GPR55
G protein-coupled receptor 55
GPR55 (G protein-coupled receptor 55) is a G protein-coupled receptor that in humans is encoded by the GPR55 gene. GPR55, along with GPR119 and GPR18, have been implicated as novel cannabinoid receptors. GPR55 is activated by the plant cannabinoids 9-THC and cannabidiol, and the endocannabinoids anandamide, 2-AG, noladin ether in the low nanomolar range. Recent research suggests that lysophosphatidylinositol and its 2-arachidonoyl derivative may be the endogenous ligands for GPR55, and the receptor appears likely to be a possible target for treatment of inflammation and pain as with the other cannabinoid receptors. The physiological role of GPR55 is unclear. GPR55 has been proposed as a new potential drug target for the treatment of diabetes, Parkinson’s disease, neuropathic pain, and cancer.
All Product Categories
-
GPR55 Related Products (27)
Related Products (27)
- 1
- 2
-
Tocrifluor 1117
0 ImagesCat. No.: HY-103336CAS No.: 1186195-59-4Synonyms: T1117Tocrifluor 1117 is a selective GPR55 ligand and fluorescent probe. Tocrifluor 1117 shows extremely low affinity for mouse CB1 receptors (Ki >1000 nM) and only weakly displaces CB1 agonists. Tocrifluor 1117 specifically activates GPR55 to trigger intracellular calcium oscillations, and binds to vascular smooth muscle, endothelial and adventitial cells; all these binding effects are inhibited by pretreatment with unlabeled AM251 or O1602. Tocrifluor 1117 can clearly visualize the distribution of GPR55 in vascular tissues via confocal microscopy, while its uptake in cancer cells is completely dependent on GPR55 expression.
-
CID 16020046 (Standard)
0 ImagesCID 16020046 (Standard) is the analytical standard of CID 16020046. This product is intended for research and analytical applications. CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC50 of 0.15 μM. CID 16020046 inhibits GPR55-mediated Ca2+ signaling and GPR55-mediated ERK1/2 phosphorylation. CID 16020046 reduces wound healing in endothelial cells and is involved in the regulation of platelet function.
-
ML-193 (Standard)
0 ImagesCat. No.: HY-110125RCAS No.: 713121-80-3Synonyms: CID 1261822 (Standard)ML-193 (Standard) is the analytical standard of ML-193 (HY-110125). This product is intended for research and analytical applications. ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of ParKinson’s disease (PD) rats.
-
GSK494581A
0 ImagesCat. No.: HY-111162CAS No.: 909416-67-7
-
O-1602 (Standard)
0 ImagesCat. No.: HY-107541RCAS No.: 317321-41-8O-1602 (Standard) is the analytical standard of O-1602. This product is intended for research and analytical applications. O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1.
-
CID1172084
0 ImagesCat. No.: HY-123302CAS No.: 459848-10-3
-
ML191 (Standard)
0 ImagesCat. No.: HY-111083RCAS No.: 931695-79-3Synonyms: CID23612552 (Standard)ML191 (Standard) is the analytical standard of ML191 (HY-111083). This product is intended for research and analytical applications. ML-191 is an antagonist of GPR55. It inhibits GPR55 signaling induced by lysophosphatidylinositol (EC50=1.076 µM in U2OS cells overexpressing GPR55). ML-191 inhibits LPI-induced phosphorylation of ERK1/2 (IC50=328 nM) and receptor-dependent translocation of PKCβII when used at a concentration of 30 µM.
- 1
- 2
